0001567619-22-003042.txt : 20220209
0001567619-22-003042.hdr.sgml : 20220209
20220209160641
ACCESSION NUMBER: 0001567619-22-003042
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220207
FILED AS OF DATE: 20220209
DATE AS OF CHANGE: 20220209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Peppe Jennifer
CENTRAL INDEX KEY: 0001861060
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40604
FILM NUMBER: 22607225
MAIL ADDRESS:
STREET 1: IMAGO BIOSCIENCES, INC.
STREET 2: 329 OYSTER POINT BLVD. 3RD FL
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Imago BioSciences, Inc.
CENTRAL INDEX KEY: 0001623715
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 454915810
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650 325 5156
MAIL ADDRESS:
STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2022-02-07
0
0001623715
Imago BioSciences, Inc.
IMGO
0001861060
Peppe Jennifer
C/O IMAGO BIOSCIENCES, INC.
329 OYSTER POINT BLVD, 3RD FLOOR
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
See Remarks
Common Stock
2022-02-07
4
M
0
7000
1.52
A
155809
D
Common Stock
2022-02-07
4
M
0
6000
2.52
A
161809
D
Common Stock
2022-02-07
4
S
0
7100
20.1776
D
154709
D
Common Stock
2022-02-07
4
S
0
5900
20.8374
D
148809
D
Stock Option (Right to Buy)
1.52
2022-02-07
4
M
0
7000
0.00
D
2029-04-09
Common Stock
7000
17094
D
Stock Option (Right to Buy)
2.52
2022-02-07
4
M
0
6000
0.00
D
2021-01-01
2027-03-28
Common Stock
6000
73551
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The transaction was executed in multiple trades in prices ranging from $19.74 to $20.72, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The transaction was executed in multiple trades in prices ranging from $20.74 to $20.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Senior Vice President, Clinical Operations
/s/ Hugh Rienhoff, as Attorney-in-fact for Jennifer Peppe
2022-02-09